Optimal Stereotactic Body Radiotherapy Dosage for Hepatocellular Carcinoma

doi 10.1101/2020.02.27.20028621
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Cold Spring Harbor Laboratory

Related search

Current Status of Stereotactic Body Radiotherapy for the Treatment of Hepatocellular Carcinoma

Yeungnam University Journal of Medicine
2019English

Optimal Patient Selection for Stereotactic Body Radiotherapy

The Lancet Oncology
Oncology
2019English

Safety and Efficacy of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma With Portal Vein

HPB
HepatologyGastroenterology
2018English

Locoregenional Therapy for Hepatocellular Carcinoma: Transarterial Chemoembolization Versus Transarterial Radioembolization Versus Stereotactic Body Radiotherapy

Clinical Liver Disease
Hepatology
2019English

Optimal Patient Selection for Stereotactic Body Radiotherapy – Authors' Reply

The Lancet Oncology
Oncology
2019English

Thymic Carcinoma Treated by CyberKnife Stereotactic Body Radiotherapy

Cureus
2017English

Baseline Albumin-Bilirubin (ALBI) in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiotherapy (SBRT)

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2018English

Stereotactic Body Radiotherapy for Pancreatic Cancer

Hong Kong Journal of Radiology
Nuclear MedicineRadiologyImaging
2017English

Multicenter Planning Comparison of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma With Major Portal Vein Tumor Thrombosis (KROG 16-17)

Journal of Liver Cancer
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy